Business Wire

AFC Energy launches Hyamtec Limited (“Hyamtec”) to unlock the global hydrogen value chain

18.9.2024 09:00:00 CEST | Business Wire | Press release

Share

Delivering next generation Ammonia Cracking Technology

Hyamtec, the UK’s newest hydrogen company, has been launched by AFC Energy plc to deliver next generation modular ammonia cracking technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918101995/en/

Aerial view of ammonia cracker site (Photo: Business Wire)

Hyamtec can make on-site, on-demand hydrogen at just 10% of the cost of truck delivered hydrogen and will prioritise natural gas displacement in the hard to abate heavy industrial sectors which account for 50% of global carbon emissions.

Hyamtec will target areas which represent a £40 billion market in the UK alone:

  • Hydrogen rich combustible fuel gas for the decarbonisation of industrial heat generation;
  • Ammonia conversion of large combustion engines for power generation, marine and mining; and
  • Modular purified hydrogen production for fuel cells and transportation.

Hydrogen is the solution for decarbonisation of heavy industry and green hydrogen plants will dominate new capacity and by 2030, up to 20% of hydrogen produced globally will be green. This production will be located where the renewable energy required is abundant plentiful and cheap; however, hydrogen is difficult to store and transport, and it will take decades to install hydrogen pipelines. To transport the hydrogen to where it will be used, typically thousands of miles away, will require it to be moved as ammonia and then converted back to hydrogen.

Hyamtec’s technology can achieve this on-site at the lowest cost and highest efficiency to provide a solution to unlock industrial decarbonisation at scale. Hyamtec crackers have proven their ability to integrate with ammonia combustion engines (as a pilot fuel) and to deliver ISO Grade hydrogen for use in fuel cell applications.

Dr. Mike Rendall, Managing Director of Hyamtec Limited, said:

“Hyamtec is focused on fast tracking the decarbonisation of industry through ammonia and our ammonia cracking technologies. With over £40bn spent per annum on natural gas by industrial users in the UK alone, the global opportunity to displace fossil fuels in industry with ammonia is immense.

“The global journey to net zero will require the rapid development of hydrogen-based technologies. We look forward to partnering with industry to support the rapid decarbonisation of the world’s hardest to abate sectors and to announcing Hyamtec’s first commercial deals soon.”

Find out more at www.hyamtec.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918101995/en/

Contacts

Hyamtec Ltd

Hyamtec Ltd
Mike Rendall, Managing Director
+44 (0) 14 8327 6726
FTI Consulting – PR Advisors
afcenergy@fticonsulting.com

afcenergy@fticonsulting.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release

€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye